The Phase I trial of ADC CX-2051 in colorectal cancer will continue, based on a decision made by a safety committee.

With a solid cash position and expected profitability by late 2026, Apellis stock is set for recovery. Read the latest ...

The combination of Padcev and Keytruda delivered a phase 3 win in muscle-invasive bladder cancer. China did not renew the conditional approval for a controversial Alzheimer's disease drug. | The ...

For the first time, the FDA has approved a treatment for recurrent respiratory papillomatosis (RRP), a rare, chronic disease that causes benign tumors, most commonly in the voice box, and can force ...

The vitiligo treatment landscape is evolving with a shift towards targeted therapies, which have shown encouraging results in promoting repigmentatio ...